## Abstract To define the involvement of __p16/CDKN2__ and __p15/MTS2__ tumorβsuppressor genes for response to chemotherapy in primary epithelial ovarian cancer, we analyzed alterations of the gene in 45 patients who were treated with primary cytoreductive surgery followed by 6 courses of cisβdiamm
Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors
β Scribed by Yoshihito Ichikawa; Sadao Yoshida; Yumi Koyama; Misako Hirai; Tomoyoshi Ishikawa; Masato Nishida; Hajime Tsunoda; Takeshi Kubo; Masanao Miwa; Kazuhiko Uchida
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- French
- Weight
- 520 KB
- Volume
- 69
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## BACKGROUND. Alterations of the suppressor genes, such as the retinoblastoma (RB), p53, pl6(CDKN2), and p15 genes, have been reported in human gliomas. These genes have been suggested as the cell cycle regulatory genes at the G,-S checkpoint.
The tumor suppressor gene CDKN2 (p16/MTS1) resides on chromosome 9p21 and encodes a 16 kDa inhibitor of the cyclin-dependent kinases. Inactivation of CDKN2 by homozygous deletion, point mutation, and recently described aberrant methylation in the 5' promoter region may increase progression through t
Loss of heterozygosity on chromosome 9 has been reported in a variety of human cancers. The cyclin-dependent kinase inhibitor p16 gene, mapped on chromosome 9p21, is presumed to be the tumor-suppressor gene localized in this chromosome. The aim of our study was to determine, in 26 Barrett's adenocar
The tumor suppressor gene CDKN2A (MTS1/p16), located on chromosome 9p21, is inactivated in a variety of tumors including melanomas and tumors of the biliary tract, pancreas, and stomach. The aim of the present study was to determine whether this gene is inactivated in hepatocellular carcinoma (HCC).
The G 1 /S checkpoint of the cell cycle is regulated by p16, p53 and RB tumor suppressor genes. Loss of expression of the p16 INK4 tumor suppressor protein, the product of the CDKN2 gene, has been associated with a wide variety of human malignancies. Mutations, loss of heterozygosity and deletions o